0001596771-18-000019.txt : 20180212 0001596771-18-000019.hdr.sgml : 20180212 20180212163100 ACCESSION NUMBER: 0001596771-18-000019 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180208 FILED AS OF DATE: 20180212 DATE AS OF CHANGE: 20180212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gullans Steven R. Ph.D. CENTRAL INDEX KEY: 0001571997 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37809 FILM NUMBER: 18596863 MAIL ADDRESS: STREET 1: C/O EXCEL VENTURE MANAGEMENT, LLC STREET 2: 800 BOYLSTON ST., STE 2825 CITY: BOSTON STATE: MA ZIP: 02199 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gemphire Therapeutics Inc. CENTRAL INDEX KEY: 0001638287 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472389984 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 17199 N. LAUREL PARK DRIVE STREET 2: SUITE 401 CITY: LIVONIA STATE: MI ZIP: 48152 BUSINESS PHONE: 248-980-6538 MAIL ADDRESS: STREET 1: 17199 N. LAUREL PARK DRIVE STREET 2: SUITE 401 CITY: LIVONIA STATE: MI ZIP: 48152 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2018-02-08 0 0001638287 Gemphire Therapeutics Inc. GEMP 0001571997 Gullans Steven R. Ph.D. 17199 N. LAUREL PARK DRIVE SUITE 401 LIVONIA MI 48152 1 1 0 0 Interim President & CEO Common Stock 2018-02-08 4 P 0 71429 7 A 930252 I Held by Excel Venture Fund II, L.P. The shares were purchased in a confidentially marketed public offering pursuant to an Underwriting Agreement. The offering closed on February 12, 2018. The reporting person, as the Manager of Excel Venture Fund II, L.P., beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. /s/ Stephanie Swan, by Power of Attorney 2018-02-12